Dark
Streaming/Mobile
OldĀ Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:44:47 EDT Sat 12 Jul 2025
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:APTO
- APTOSE BIOSCIENCES INC -
https://aptose.com
04:44:47 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
APTO
- Q
DEFUNCT
1.71
51.609 2.3937
Apr 01
May 05
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Up
-- UPC Restricted:
No
Financial Status:
Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - All 0 today
More trades...
Time ET
Ex
Price
Change
Volume
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2025-05-05 07:00
U:APTO
News Release
200
Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
2025-04-23 17:00
U:APTO
News Release
200
Aptose Announces Auditor Not Standing for Re-Appointment
2025-04-23 07:30
U:APTO
News Release
200
Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
2025-04-01 08:30
U:APTO
News Release
200
Aptose Common Shares to Delist from Nasdaq as of April 2, 2025
2025-03-28 08:02
U:APTO
News Release
200
Aptose Reports Year End 2024 Results and Corporate Highlights
2025-03-17 07:30
U:APTO
News Release
200
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
2025-02-20 07:32
U:APTO
News Release
200
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
2025-02-18 16:30
U:APTO
News Release
200
Aptose Announces Reverse Share Split
2025-02-13 16:30
U:APTO
News Release
200
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
2025-02-12 07:00
U:APTO
News Release
200
Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
2025-01-09 16:00
U:APTO
News Release
200
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
2024-12-19 16:05
U:APTO
News Release
200
Aptose Announces Positive Decision by Nasdaq Hearings Panel
2024-12-12 10:15
U:APTO
News Release
200
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
2024-12-09 12:00
U:APTO
News Release
200
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
2024-12-03 07:30
U:APTO
News Release
200
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
2024-11-25 16:15
U:APTO
News Release
200
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
2024-11-22 08:00
U:APTO
News Release
200
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
2024-11-20 07:30
U:APTO
News Release
200
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
2024-11-08 16:01
U:APTO
News Release
200
Aptose Reports Results for the Third Quarter 2024
2024-09-05 16:15
U:APTO
News Release
200
Aptose Announces Results from Special Meeting of Shareholders